Future Revenue from DRI Future Revenue Future Revenue Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Percentage of employee vested contribution Defined Contribution Plan, Employees Contribution, Vested Percentage Percentage vested of employee's contributions to defined contribution plan DRI Healthcare Acquisitions LP (DRI) DRI Healthcare Acquisitions LP (DRI) [Member] DRI Healthcare Acquisitions LP (DRI) Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment [Abstract] Undesignated preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Property, equipment and software Property, Plant and Equipment, Gross Lease liabilities Increase (decrease) in lease liabilities Increase (decrease) in lease liabilities SEC Schedule, 12-09, Reserve, Inventory SEC Schedule, 12-09, Reserve, Inventory [Member] Income Tax Disclosure [Abstract] Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Boehringer Collaboration and License Agreement Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member] Boehringer Ingelheim International GmbH Collaboration And License Agreement Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities NIAID National Institute of Allergy and Infectious Diseases [Member] Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies. Software Software and Software Development Costs [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Financial Instruments [Domain] Financial Instruments [Domain] Range Statistical Measurement [Domain] Discount rate Lessee, Operating Lease, Discount Rate Depreciation expense Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net deferred income tax asset/(liability) Deferred Tax Assets, Net Estimated Useful Lives Property Plant And Equipment Estimated Useful Life Table [Table Text Block] Property plant and equipment estimated useful life. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock U.S. Federal Government Domestic Tax Authority [Member] Other non-cash items Other Noncash Income (Expense) McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC [Member] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive stock options Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Tax Period [Domain] Tax Period [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Collaborative arrangement, term Collaborative Arrangement, Term Collaborative Arrangement, Term Share-Based Payment Arrangement, Option, Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Revenue Collaboration And License Agreements Disclosure [Text Block] The entire disclosure for collaboration and license agreements. Accumulated other comprehensive loss AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Total assets measured at fair value Assets, Fair Value Disclosure Number of Shares (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Increases for current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Right of Use asset and Lease Liability Increase Right of Use asset and Lease Liability Increase Right of Use asset and Lease Liability Increase Securities Fair Value Debt Securities, Available-for-Sale Collaborative arrangement, extension term Collaborative Arrangement, Extension Term Collaborative Arrangement, Extension Term Non-refundable upfront payment Non-refundable upfront payment Initial fee received from collaboration or license agreement. Forfeited or expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] State net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, State and Local Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets, Level 1 Fair Value, Inputs, Level 1 [Member] Employee Stock Employee Stock [Member] Weighted-average remaining contractual term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Milestone from DRI Future Milestone Future Milestone Term of agreement (in years) Collaboration And License Agreement, Term Collaboration And License Agreement, Term Proceeds from stock option exercises and ESPP purchases Proceeds from Stock Options Exercised And ESPP Purchases Proceeds from Stock Options Exercised And ESPP Purchases Net Cash Provided by (Used in) Operating Activities, Total Net Cash Provided by (Used in) Operating Activities upfront and fixed payments upfront and fixed payments upfront and fixed payments Lease liabilities Operating Lease, Liability, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Deferred income tax adjustments Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments. Other permanent items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Indefinite Indefinite [Member] Indefinite Percentage of employee contribution to salary Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Provention Bio CMO Agreeemnt Provention Bio CMO Agreeemnt [Member] Provention Bio CMO Agreeemnt Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Total liabilities Liabilities Weighted average lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of product candidates to develop Number Of Product Candidates Number Of Product Candidates Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Potential development and regulatory milestone payments Potential Development and Regulatory Milestone Payments Under Agreement Potential Development and Regulatory Milestone Payments Under Agreement Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Increases/(decreases) for prior year tax positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing At The Market Offering At The Market Offering [Member] At The Market Offering [Member] 2022 Gilead Collaboration And License Agreement 2022 Gilead Collaboration And License Agreement [Member] 2022 Gilead Collaboration And License Agreement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Undesignated preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Stock Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Imab Imab [Member] Imab Estimated useful lives Property, Plant and Equipment, Useful Life Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Tax withholding Non-refundable Payment, Tax Withholding Non-refundable Payment, Tax Withholding Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Product and Service [Domain] Product and Service [Domain] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Exercise Price Range [Axis] Exercise Price Range [Axis] Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Financial Instrument [Axis] Financial Instrument [Axis] Deferred income tax liabilities: Components of Deferred Tax Liabilities [Abstract] Motor vehicles Vehicles [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Subsequent Event Subsequent Event [Member] Sales revenue, net Revenue Benchmark [Member] Revenue from collaborative agreements Revenue From Collaborative Agreements [Member] Revenue From Collaborative Agreements Zai Lab Clinical Supply Agreements Zai Lab Clinical Supply Agreements [Member] Zai Lab Clinical Supply Agreements Document Period End Date Document Period End Date Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Potential milestone payment to third parties for intellectual property under agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Interest Income, Other Interest Income, Other Total assets Assets Cost of manufacturing services Cost of manufacturing services Cost of manufacturing services Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Operating lease ROU assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Tax Year 2025 To 2037 Tax Year 2025 To 2037 [Member] Tax Year 2025 To 2037 Summary of Fair Value Measurement Financial Assets Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Incyte MGA012 Clinical Services Incyte Commercial Supply Agreement [Member] Incyte Commercial Supply Agreement Antidilutive Securities [Axis] Antidilutive Securities [Axis] Balance (in shares) Balance (in shares) Shares, Issued Accrued expenses and other current liabilities Accrued Liabilities, Current Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Net Cash Provided by (Used in) Financing Activities, Total Net Cash Provided by (Used in) Financing Activities Orphan drug credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Development milestones Development Milestones, Amount Development Milestones, Amount I-Mab Biopharma Collaboration And License Agreement Clinical Supply I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member] I-Mab Biopharma Collaboration And License Agreement Clinical Supply ASD Healthcare and Oncology Supply ASD Healthcare and Oncology Supply [Member] ASD Healthcare and Oncology Supply Auditor Information [Abstract] Auditor Information Amounts recognized Development milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Variable lease cost Variable Lease, Cost Potential milestone payments and royalties on product sales Potential Milestone Payments and Royalties On Product Sales Potential Milestone Payments and Royalties On Product Sales Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Incyte MGA012 Supply Agreement Incyte Clinical Supply Agreement [Member] Incyte Clinical Supply Agreement Customer [Axis] Customer [Axis] Schedule of Employee Stock Options Award Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Synaffix B.V. Synaffix B.V. [Member] Synaffix B.V. Cash, Cash Equivalents and Marketable Securities Cash and Cash Equivalents, Policy [Policy Text Block] Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Domain] Award Type [Domain] 2018 Zai Lab Collaboration And License Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement Unrecognized compensation expense recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2016 Employee Stock Purchase Plan Two Thousand Sixteen Employee Stock Purchase Plan [Member] Two Thousand Sixteen Employee Stock Purchase Plan [Member] Weighted-average remaining contractual term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Undesignated Preferred Stock Undesignated Preferred Stock [Member] Undesignated Preferred Stock [Member] Computer equipment Computer Equipment [Member] Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues One Time Millstone Credit One Time Millstone Credit One Time Millstone Credit Subsequent Event Subsequent Events [Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Range of Exercise Price, upper limit Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Incyte Corporation (Incyte) Incyte Corporation [Member] Incyte Corporation [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Employee Benefit Plan Retirement Benefits [Text Block] RevenuesFromGrantsMember RevenuesFromGrantsMember Exercise Price Range From Dollars 15.01 to 25.00 Member Exercise Price Range From Dollars 15.01 to 25.00 Member [Member] Exercise Price Range From Dollars 15.01 to 25.00 Member Asset Class [Domain] Asset Class [Domain] Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Eligible age to participate in plan Employees Eligible Age To Participate In Benefit Plan Refers to minimum eligible age of employee to participate in benefit plan. Equity-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Trading Symbol Trading Symbol Entity File Number Entity File Number Increased number of shares authorized (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase Share based compensation arrangement by share based payment award number of shares authorized after increase. Deferred revenue, noncurrent Contract with Customer, Liability, Noncurrent Weighted-Average Remaining Contractual Life in Years Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Research and development Research and Development Expense Deferred revenue Deferred Revenue, Current Lab equipment Equipment [Member] Total Annual Fixed Payments Total Annual Fixed Payments Total Annual Fixed Payments Granted (in shares) Awards granted in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units Restricted Stock Units (RSUs) [Member] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Research credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] I-Mab Biopharma I-Mab Biopharma [Member] I-Mab Biopharma Accounts payable Increase (Decrease) in Accounts Payable Zai Lab Limited (Zai Lab) Zai Lab Limited [Member] Zai Lab Limited Percentage of significant accounts receivable Concentration Risk, Percentage Subsequent Events [Abstract] Subsequent Events [Abstract] Revenues Revenues Additional Annual Fixed Payments Additional Annual Fixed Payments Additional Annual Fixed Payments Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Earnings Per Share, Basic Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Construction in progress Construction in Progress, Gross Inventory Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Prepaid expenses and other current assets Prepaid Expense, Current US Federal tax credits carry forward Tax Credit Carryforward, Amount Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Debt Securities, Available-for-sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Other Deferred Tax Assets, Other Entity Interactive Data Current Entity Interactive Data Current Sale of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Remaining portion of net operating losses Operating Loss Carryforwards Not Subject To Limitation Operating loss carryforwards not subject to limitation. Stock warrants (in shares) Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Government-sponsored enterprises Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Transaction price Collaborative Agreement Transaction Price Collaborative Agreement Transaction Price Lease, Cost Lease, Cost Common Stock Common Stock [Member] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Lease, Cost Lease, Cost [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Revenue Recognition Revenue [Policy Text Block] Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Statement [Table] Statement [Table] Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Lease renewal term (in years) Lessee, Operating Lease, Renewal Term Furniture Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Unrecognized interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Research and development credit, net Deferred Tax Assets, Tax Credit Carryforwards, Research Range [Axis] Statistical Measurement [Axis] Revenue from government agreements Revenue From Government Agreements [Member] Revenue From Government Agreements Exercise Price Range From Dollars 25.01 to 40.21 Member Exercise Price Range From Dollars 25.01 to 40.21 Member [Member] Exercise Price Range From Dollars 25.01 to 40.21 Member Exercise Price Range From Dollars 0.94 to 5.00 Member Exercise Price Range From Dollars 0.94 to 5.00 Member [Member] Exercise Price Range From Dollars 0.94 to 5.00 Member Consideration received common stock warrant exercise price (in usd per share) Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Fair Value, Recurring Fair Value, Recurring [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Statement [Line Items] Statement [Line Items] Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total potential value Total potential value of agreement Refers to total potential value under agreement. 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Provision for federal or state income taxes Current Income Tax Expense (Benefit) Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product Product [Member] Operating lease, ROU Assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule Of Supplemental Balance Sheet Information, Operating Leases Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block] Schedule Of Supplemental Balance Sheet Information, Operating Leases Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Federal U.S. net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, Domestic Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t U.S. Federal and State Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax expense/(benefit) Income Tax Expense (Benefit) Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property, Equipment and Software Property, Plant and Equipment, Policy [Policy Text Block] Potential commercial milestone payments Potential Commercial Milestone Payments Under Agreement Potential Commercial Milestone Payments Under Agreement Undesignated preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Entity Public Float Entity Public Float Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Cost of product sales Cost of Goods and Services Sold Prepaid expenditures Deferred Tax Liabilities, Prepaid Expenses Diluted weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Potential proceeds from royalties percent Proceeds from Royalties, Percent Proceeds from Royalties, Percent Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accounts receivable Accounts Receivable [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Net operating losses limited for use utilized on an annual basis Operating Loss Carryforwards Annual Limitation Amount Amount of net operating loss which are limited for use, utilized on a annual basis. Marketable securities Investments Investments Equity Incentive Plan 2003 Equity Incentive Plan 2003 [Member] Equity Incentive Plan 2003 Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,701,467 and 61,307,428 shares outstanding at December 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate intrinsic value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Undesignated preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Text Block [Abstract] Text Block [Abstract] Incyte MGA012 Agreement Incyte MGA012 Agreement [Member] Incyte MGA012 Agreement Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Cash proceeds from exercise of stock options Proceeds from Stock Options Exercised Weighted-average remaining contractual term, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Concentration Risk [Line Items] Concentration Risk [Line Items] Deferred revenue, current Contract with Customer, Liability, Current Capital Expenditures Incurred but Not yet Paid Capital Expenditures Incurred but Not yet Paid Orphan drug credit, net Deferred Tax Assets, Tax Credit Carryforwards, Other Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net Cash Provided by (Used in) Investing Activities, Total Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Laboratory and office equipment Laboratory and Office Equipment [Member] A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine. Deferred income tax assets: Components of Deferred Tax Assets [Abstract] Other non current assets Other Assets, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization Depreciation, Depletion and Amortization Percent of fair market value to purchase shares Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Milestones Value Added Tax Milestones Value Added Tax Milestones Value Added Tax Additions Charged to Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Counterparty Name [Axis] Counterparty Name [Axis] Exercise Price Range From Dollars 5.01 to 15.00 Member Exercise Price Range From Dollars 5.01 to 15.00 Member [Member] Exercise Price Range From Dollars 5.01 to 15.00 Member Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Provention PRV3279 Provention PRV3279 [Member] Provention PRV3279 Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Stock options and RSUs Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units Janssen Biotech Inc. Janssen Biotech Inc [Member] Counterparty in collaboration agreement Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaboration and Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Property, equipment and software, net Property, equipment and software, net Property, Plant and Equipment, Net Operating lease payments Operating Lease, Payments Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income Other Nonoperating Income (Expense) OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Sale of common stock (in dollars per share) Sale of Stock, Price Per Share Stock plan related activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Maximum Maximum [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventory, Work in Process, Gross Inventory, Work in Process, Gross Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Asset Purchase Agreement Asset Purchase Agreement [Member] Asset Acquisition Agreement Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Common stock purchased by employees (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Provention Bio Milestone Revenue in A/R Receivable from collaboration partner Receivable from collaboration partner Premium received on stock purchase Premium received on stock purchase Amount by which purchase price exceeds fair value for common stock purchased by collaborator. Zai Lab Agreement Zai Labs Collaboration And License Agreement [Member] Zai Labs Collaboration And License Agreement Revenues: Revenues [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Cost of Product Sales and Cost of Manufacturing Services Cost of Goods and Service [Policy Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Section 174 deferred tax asset Section 174 deferred tax asset Section 174 deferred tax asset Unrecognized compensation cost related to non-vested stock-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Gilead Gilead [Member] Gilead Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] RevenuesFromCMOAmendmentAgreement RevenuesFromCMOAmendmentAgreement [Member] RevenuesFromCMOAmendmentAgreement Summary of Percentage of Customer Concentration Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Property, Equipment and Software Property, Plant and Equipment Disclosure [Text Block] Sublease Income Sublease Income Aggregate intrinsic value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization and Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Total costs and expenses Costs and Expenses Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Common stock, shares issued (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Line Items] Class of Stock [Line Items] Operating lease liabilities Operating Lease, Liability Balance at Beginning of Year Balance at End of Year SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Investments, Debt and Equity Securities [Abstract] Liabilities and stockholders' equity Liabilities and Equity [Abstract] U.S Treasury securities U.S. Treasury securities US Treasury Securities [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Inventory, net Inventory, Net Revenue from variable consideration recognize Revenue from variable consideration recognize Revenue from variable consideration recognize Accounts payable Accounts Payable, Current Net operating loss for limited use Operating Loss Carryforwards Limitations On Use Amount Amount of net operating loss carryforward, which are limited for use over the range of years. Income Tax Authority [Axis] Income Tax Authority [Axis] Other non current assets Increase (Decrease) in Other Operating Assets Aggregate intrinsic value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Auditor Location Auditor Location Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Basic weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-cash operating and investing activities Noncash Investing and Financing Items [Abstract] Security Exchange Name Security Exchange Name Weighted average exercise price (in dollars per share) Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Upfront Payment from DRI Health Trust Upfront Payment Upfront Payment Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Cover [Abstract] Leases Lessee, Leases [Policy Text Block] Entity Voluntary Filers Entity Voluntary Filers Number of Shares (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Stock-based Compensation Share-Based Payment Arrangement [Text Block] Percentage of common stock share outstanding Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan. Deferred revenue Deferred Tax Assets, Deferred Income Maximum employee contribution percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Janssen Collaboration And License Agreement Janssen Collaboration And License Agreement [Member] Janssen Collaboration And License Agreement Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Components of the Company's Deferred Income Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gross deferred income tax assets Deferred Tax Assets, Gross Stock Options Exercisable Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Zai Lab Zai Labs [Member] Zai Labs Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Earnings Per Share, Diluted Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Exercise Price Range [Domain] Exercise Price Range [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Collaboration Arrangement, One-time Credit Paid, Percent Collaboration Arrangement, One-time Credit Paid, Percent Collaboration Arrangement, One-time Credit Paid, Percent 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Customer Concentration Risk Customer Concentration Risk [Member] Beginning balance Ending balance Unrecognized Tax Benefits Net deferred income tax assets Deferred Tax Assets, Net of Valuation Allowance Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH [Member] Boehringer Ingelheim International GmbH Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Provention PRV031 Provention PRV031 [Member] Provention PRV031 Zai Lab Collaboration And License Agreement Zai Lab Collaboration And License Agreement [Member] Zai Lab Collaboration And License Agreement Gross unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Range of Exercise Price, lower limit Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Deferred revenue Contract with Customer, Liability I-Mab Biopharma Collaboration And License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Deferred revenue, net of current portion Deferred Revenue, Noncurrent Les Laboratoires Servier And Institut De Recherches Servier (Servier) Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member] Les Laboratoires Servier And Institut De Recherches Servier (Servier) Furniture and office equipment Furniture And Office Equipment [Member] Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation. Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Inventory valuation reserves Inventory Valuation Reserves Inventory, Net Inventory Disclosure [Text Block] Defined contribution plan, employer discretionary contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Revenue From Performance Of The Research And Development Activities Revenue From Performance Of The Research And Development Activities [Member] Revenue From Performance Of The Research And Development Activities Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Share-based compensation, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Zai Lab Zai Lab [Member] Zai Lab Gross deferred income tax liabilities Deferred Tax Liabilities, Gross Revenues From License Agreements Revenues From License Agreements [Member] Revenues From License Agreements Reconciliation of Reported Estimated Income Tax Benefit Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Other non current liabilities Increase (Decrease) in Deferred Rent The increase (decrease) during the reporting period in deferred rent. Depreciation Deferred Tax Assets, Property, Plant and Equipment Entity Central Index Key Entity Central Index Key Provention License Agreement Provention License Agreement [Member] Provention License Agreement Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Expenses, Including Clinical Trial Accruals/Expenses Research and Development Expense, Policy [Policy Text Block] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Tax Period [Axis] Tax Period [Axis] City Area Code City Area Code Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Selling, general and administrative General and Administrative Expense Assets Assets [Abstract] Retirement Benefits [Abstract] Schedule of Inventory Reserves Schedule of Inventory Reserves [Table Text Block] Schedule of Inventory Reserves Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] United States federal tax at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Asset Class [Axis] Asset Class [Axis] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Provention Bio, Inc. (Provention) Provention Bio [Member] Provention Bio Other non current liabilities Other Liabilities, Noncurrent Stock Incentive Plan 2013 Stock Incentive Plan 2013 [Member] Stock Incentive Plan 2013 [Member] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Customer [Domain] Customer [Domain] Target nomination, option fees and milestone Potential target nomination, option fees and milestone payments Potential target, nomination, option fees and milestone payments